Core Viewpoint - Wantai Biological Pharmacy Enterprise (万泰生物) announced that its subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., has successfully passed the WHO PQT–INS periodic review for its bivalent HPV vaccine, which will facilitate the company's future expansion into international markets [1] Group 1 - The bivalent HPV vaccine is the first of its kind in China and the fourth globally for the prevention of cervical cancer [1] - The vaccine is primarily intended for women aged 9 to 45 and is designed to prevent cervical cancer caused by high-risk HPV types 16 and 18, as well as related cervical lesions [1] - The vaccine targets various conditions including CIN2/3, AIS, and CIN1, along with persistent infections caused by HPV types 16 and 18 [1]

格隆汇1月26日丨智翔金泰(688443.SH)近日在线上会议交流时表示，GR1802注射液(泰利奇拜单抗)的 中、重度特应性皮炎适应症已经于2025年9月新药上市申请获受理，目前在上市申请审评阶段；慢性鼻 窦炎伴鼻息肉、慢性自发性荨麻疹、成人和青少年季节性过敏性鼻炎适应症都处于Ⅲ期临床试验阶段， 哮喘处于Ⅱ期临床试验阶段。 ...

Core Viewpoint - The company expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of Zewokaiolun Injection and the acceptance of the NDA for Shurukiaolun Injection by the NMPA [1] Financial Performance - The net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zewokaiolun Injection in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in R&D expenses for both Zewokaiolun Injection and Shurukiaolun Injection [1]

Core Viewpoint - The company Kintor Pharmaceutical (02171) anticipates a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug Zeworkiobulin and the acceptance of the new drug application for Shurikiobulin by the National Medical Products Administration (NMPA) [1] Financial Performance - The expected net loss for the reporting period is projected to be no more than approximately RMB 120 million, compared to approximately RMB 798 million for the fiscal year ending December 31, 2024 [1] - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, compared to approximately RMB 789 million for the fiscal year ending December 31, 2024 [1] Factors Influencing Loss Reduction - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin in mainland China [1] - Impact of foreign exchange fluctuations [1] - Significant reduction in research and development expenses for both Zeworkiobulin and Shurikiobulin [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug, Zeworkiobulin Injection, and the acceptance of the New Drug Application (NDA) for Shurikiobulin Injection by the National Medical Products Administration (NMPA) [1]. Financial Summary - The net loss for the fiscal year 2025 is projected to be no more than approximately RMB 120 million, a significant decrease from approximately RMB 798 million for the fiscal year ending December 31, 2024 [1]. - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, down from approximately RMB 789 million for the fiscal year ending December 31, 2024 [1]. Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin Injection in mainland China [1]. - Impact of foreign exchange fluctuations [1]. - Significant reduction in research and development expenses for both Zeworkiobulin Injection and Shurikiobulin Injection [1].

Group 1 - Company announced the receipt of a patent certificate from the United States Patent and Trademark Office for a kit used to detect soluble growth hormone expression gene 2 protein [1] - The patent is expected to enhance the company's product offerings in the biotechnology sector [1] Group 2 - International gold prices have surpassed $5000, marking a 280% increase over the past seven years [1] - Experts suggest that the future trajectory of gold prices will depend on the US dollar, international monetary system, interest rate cuts, and technological revolutions [1]

Core Viewpoint - CAR-T cell therapy, despite existing development bottlenecks, has shown excellent results and significant potential in tumor treatment, making it one of the fastest-growing segments in innovative drugs globally [1] Group 1: Industry Development and Challenges - CAR-T technology has demonstrated breakthrough therapeutic effects in hematological malignancies, but its industrialization faces challenges due to the small market size and high treatment costs associated with these indications [2] - Over 90% of new cancer cases globally in 2023 are expected to be solid tumors, indicating a vast potential market for CAR-T therapies if the technology can overcome the treatment bottlenecks for solid tumors [2] - Since 2020, more CAR-T solid tumor therapy projects have entered clinical research, with over 50% of the pipeline focusing on this area, making it a key competitive advantage for many Chinese innovative drug companies [2] Group 2: Company Strategy and Product Pipeline - The company has developed a pipeline that includes 4 autologous CAR-T and 6 universal CAR-T products, covering hematological malignancies, solid tumors, and autoimmune diseases [2] - The new drug application for CT041 (Shurike Aolun Sai Injection) has been accepted by the National Medical Products Administration of China, making it the first CAR-T cell product globally to enter the new drug application stage for solid tumors [2][3] Group 3: Cost and Accessibility - The high cost of CAR-T therapies, typically priced in the millions, poses a significant barrier to patient accessibility, necessitating solutions for affordability [5] - Universal CAR-T therapies, which can be produced in batches for multiple patients, have the potential to significantly reduce costs, with estimates showing a reduction in total material costs from $60,000 to $2,000 and production costs from $95,780 to $4,460 [5] - The company has developed innovative technologies to address the immune rejection of non-autologous cells, with patents granted in multiple regions, aiming for the first universal CAR-T product to be launched within five years [5] Group 4: Market Dynamics and Payment Solutions - The large patient base in China, especially as CAR-T therapies expand to solid tumors, presents a theoretical market space that is vast [7] - Since the approval of the first hematological CAR-T therapy, the company has received 154 valid orders across 23 provinces in 2024, indicating a growing commercial presence [7] - The introduction of the first version of the "Commercial Health Insurance Innovative Drug Directory" in 2025, which includes multiple CAR-T therapies, marks a breakthrough in addressing payment challenges and is expected to facilitate the commercial development of CAR-T therapies in China [7][8] Group 5: Policy Support and Industry Growth - The company has achieved a significant reduction in losses, with an adjusted net loss of approximately 75 million yuan in the first half of 2025, down 78.1% from the same period last year [10] - Policy support, particularly in expediting drug review and approval processes, is crucial for the successful development of the CAR-T industry in China [10] - Recent policies aimed at enhancing the review process for advanced therapies are expected to significantly shorten the R&D and commercialization cycles, improving cash flow for innovative drug companies [10][11]

Market Overview - The market experienced a downturn with the Shanghai Composite Index closing down 0.09%, the Shenzhen Component down 0.85%, and the ChiNext down 0.91% [1] - A total of 1,604 stocks rose while 3,771 stocks fell, indicating a broader market weakness [1] Precious Metals Sector - The precious metals sector saw significant gains, with gold prices surpassing $5,000 per ounce for the first time, and silver prices also rising sharply [2] - Notable stocks in this sector included Zhongjin Gold and Xibu Gold, which reached their daily limit [2] Pharmaceutical Sector - The pharmaceutical sector strengthened, with stocks like Cap Bio and Mike Bio hitting their daily limit due to concerns over a Nipah virus outbreak in India [2][4] - The outbreak has prompted increased monitoring in countries such as Thailand and Nepal [2] Oil and Gas Sector - Oil and gas stocks rallied, with Zhongman Petroleum hitting its daily limit and China National Offshore Oil Corporation (CNOOC) rising over 6% to reach a new high [5] Commercial Aerospace Sector - The commercial aerospace sector faced adjustments, with stocks like China Satellite and China Satcom hitting their daily limit [6] Large Sell Orders - Significant sell orders were noted in major stocks, with Zijin Mining seeing over 4.07 billion yuan in sell orders and China Ping An over 2.05 billion yuan [6] Market Sentiment and Policy - Analysts from CITIC Securities indicated that the current reduction in broad-based ETFs by institutional investors may be a strategy to realize profits rather than directly suppressing speculative trading [10] - The report suggests that increasing margin requirements or trading fees could be more effective in cooling market enthusiasm [10]

Group 1 - The company, Bibet (688759.SH), has announced a projected net loss for the year 2025, estimating a net profit attributable to shareholders of between -166 million yuan and -136 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -188 million yuan and -158 million yuan [1] - From 2022 to 2024, Bibet reported no operating revenue, with net profits attributable to ordinary shareholders of -188.34 million yuan, -172.76 million yuan, and -55.99 million yuan respectively; net profits excluding non-recurring gains and losses were -207.49 million yuan, -187.77 million yuan, and -158.05 million yuan respectively [1] - The net cash flow from operating activities for the same period was -127.67 million yuan, -127.37 million yuan, and -89.61 million yuan respectively [1] Group 2 - Bibet was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 28, 2025, issuing 90 million shares at a price of 17.78 yuan per share [2] - The total amount raised from the initial public offering (IPO) was 1.6 billion yuan, with a net amount of 1.49 billion yuan after deducting issuance costs, which was 513.47 million yuan less than originally planned [2] - The company intended to raise 2.004 billion yuan for new drug research and development, the construction of a research and development center in Qingyuan, and to supplement working capital [2]

Market Overview - The market experienced a downturn with the Shanghai Composite Index closing down 0.09%, the Shenzhen Component down 0.85%, and the ChiNext Index down 0.91% [1] - A total of 1,604 stocks rose while 3,771 stocks fell, indicating a broader market decline [2] Precious Metals Sector - The precious metals sector saw significant gains, with stocks like Zhongjin Gold and Western Gold hitting the daily limit [3] - Spot gold prices surpassed $5,000 per ounce for the first time, while silver prices also surged [4] Pharmaceutical Sector - The pharmaceutical sector strengthened collectively, with stocks such as Cap Bio and Mike Bio reaching the daily limit [3] - The rise was attributed to concerns over a Nipah virus outbreak in India's West Bengal, prompting increased monitoring in Thailand and Nepal [5] Oil and Gas Sector - Oil and gas stocks rallied, with Zhongman Petroleum hitting the daily limit and China National Offshore Oil Corporation rising over 6% to reach a new high [6] Commercial Aerospace Sector - The commercial aerospace sector faced adjustments, with stocks like China Satellite and China Satcom hitting the daily limit [7] Large Sell Orders - Notable large sell orders were observed, with Zijin Mining having over 4.07 billion yuan in sell orders, China Ping An over 2.05 billion yuan, and Jiangxi Copper over 1.93 billion yuan [7][10] Policy Impact - According to research from招商证券, the government's measures to cool the market are intensifying to prevent significant fluctuations, suggesting a more stable outlook for A-shares in the future [10] - CITIC Securities noted that the current reduction in broad-based ETFs by institutional investors may be a strategy to realize profits rather than directly suppress speculative trading [11]